Press release of the Mesothelioma Applied Research Foundation on our Annals of Oncology article

Washington,
A press release on the MARF website described our article published on Annals of Oncology:
www.ncbi.nlm.nih.gov/pubmed/28945836

“These findings identify for the first time PCFT (a protein) as a novel mesothelioma prognostic biomarker, prompting prospective trials for its validation.” Dr. Giovannetti and her team also add that preclinical data suggest that targeting PCFT-promoter methylation might eradicate pemetrexed-resistant cells characterized by low-PCFT expression. In lay terms, this means that they not only identified a new biomarker that can help predict pemetrexed’s effectiveness, but they have also suggested a way to overcome such chemo-resistance.
www.curemeso.org/2018/04/24/pemetrexeds-alimta-effectiveness-mesothelioma-treatment-improved